论文信息 - Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation - 字舞流文

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

A. Zelenetz | D. Brander | S. Schuster | A. Mato | M. Shadman | P. Becker | J. Svoboda | S. Nasta | L. Roeker | C. Dorsey | K. Kennard | D. Landsburg | P. Sportelli | P. Tsao | M. Purdom | H. Miskin | C. King | D. Paskalis | M. Weiss | Sunita D. Nasta | Eline T. Luning Prak | B. Morrigan | E. Prak